|
|
Volumn 21, Issue SUPPL. 5, 2006, Pages
|
|
Commentary
a
|
|
Author keywords
Biopharmaceuticals; Biosimilars; Comparative testing; Immunogenicity; Pharmacovigilance; Regulatory guidelines
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CYCLOSPORIN A;
ENALAPRIL;
EPITOPE;
GENERIC DRUG;
HUMAN GROWTH HORMONE;
IMMUNOMODULATING AGENT;
MONOCLONAL ANTIBODY;
RECOMBINANT ERYTHROPOIETIN;
SIMVASTATIN;
DRUG;
IMMUNOLOGIC FACTOR;
RECOMBINANT PROTEIN;
CHRONIC KIDNEY DISEASE;
CLINICAL PATHWAY;
DRUG APPROVAL;
DRUG CONTROL;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
HUMAN;
IMMUNOGENICITY;
KIDNEY TRANSPLANTATION;
NOTE;
PATENT;
PHARMACEUTICAL CARE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RENAL REPLACEMENT THERAPY;
TREATMENT PLANNING;
VASCULAR ACCESS;
EDITORIAL;
KIDNEY DISEASE;
METABOLISM;
PHARMACOKINETICS;
STANDARD;
HUMANS;
IMMUNOLOGIC FACTORS;
KIDNEY DISEASES;
PHARMACEUTICAL PREPARATIONS;
RECOMBINANT PROTEINS;
THERAPEUTIC EQUIVALENCY;
|
|
EID: 33748682928
PISSN: 09310509
EISSN: 14602385
Source Type: Journal
DOI: 10.1093/ndt/gfl473 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
